; (C) the identification of any entity the Secretary is contracting with to implement the program, the extent to which contractors conduct health technology assessments, the types of clinical and economic outcomes and standards used in such assessments, and the use of such assessments by the Secretary; (D) a description of the average amount of funds, full-time equivalent employees, and contractor staffing and support expended under the program for negotiation of the final maximum fair price established for a selected drug, including a breakdown of expenditures dedicated to employees as well as to contractors, and how those expenditures are apportioned across various activities; (E) the amount expended on development and maintenance of a data confidentiality policy for proprietary data as required under section 1193(c); (F) the amount expended on conducting research and analysis or evaluating data and research from external sources, including external stakeholders; (G) the amount expended to establish and maintain safeguards to prevent fraud, waste, and abuse in the program as described in paragraph (B); and (H) the amount of staff time and funds expended under the program on resolving disputes with manufacturers or other stakeholders over the accuracy of data used by the Secretary and how such data is interpreted by the Secretary. (2) Limitation The Secretary shall ensure that reports under paragraph (1) do not disclose trade secrets or other proprietary information. (b) Limitation on use of funding Except as otherwise provided in this part, none of the funds provided under section 11004 of Public Law 117–169 shall be available for obligation or expenditure through a reprogramming or transfer of funds that— (1) creates a new program; (2) eliminates a program, project, or activity; (3) increases funds or personnel for any program, project, or activity for which funds have been denied or restricted by the Congress; (4) proposes to use funds directed for a specific activity by this part for a different purpose